Lead Generation Department, AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA.
Drug Discov Today. 2010 Sep;15(17-18):704-16. doi: 10.1016/j.drudis.2010.06.008. Epub 2010 Jun 23.
A new class of instruments offers an unprecedented combination of label-free detection with exquisite sensitivity to live-cell responses. These instruments can quantify G-protein-coupled receptor (GPCR) signaling through G(s), G(i) and G(q) pathways and in some cases distinguish G-protein coupling, with sensitivity high enough to detect endogenous receptors. Here, we review emerging data evaluating impedance- and optical-based label-free instruments for GPCR drug discovery. In comparison with traditional GPCR assays, we highlight strengths, weaknesses and future opportunities for label-free biosensors. The ability to qualitatively distinguish G-protein coupling has groundbreaking potential for assessing functional selectivity, a concept that is changing the way GPCR pharmacology is defined and screening strategies are designed.
一类新的仪器提供了前所未有的无标记检测与对活细胞反应的极高灵敏度的结合。这些仪器可以通过 G(s)、G(i)和 G(q)途径定量测定 G 蛋白偶联受体 (GPCR)信号,在某些情况下还可以区分 G 蛋白偶联,其灵敏度足以检测内源性受体。在这里,我们回顾了评估用于 GPCR 药物发现的基于阻抗和光学的无标记仪器的新兴数据。与传统的 GPCR 测定相比,我们强调了无标记生物传感器的优势、劣势和未来机遇。能够定性地区分 G 蛋白偶联具有开创性的潜力,可用于评估功能选择性,这一概念正在改变 GPCR 药理学的定义和筛选策略的设计方式。